Ovid Therapeutics
OVID
49 hedge funds and large institutions have $41.9M invested in Ovid Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 48 → 49 (+1)
1.07% less ownership
Funds ownership: 31.09% → 30.02% (-1.1%)
30% less capital invested
Capital invested by funds: $59.7M → $41.9M (-$17.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$4.61M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$593K |
| 3 |
Millennium Management
New York
|
+$577K |
| 4 |
CI
Cowen Inc
New York
|
+$341K |
| 5 |
State Street
Boston,
Massachusetts
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$3.08M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.26M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.44M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.27M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$882K |
OVID Hedge Fund Activity: Q3 2018 in Review
49 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2018, worth a combined $41.9M — down 30% from $59.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OVID positions and 7 closed out — a net gain of 1 holder — while 20 added to existing stakes and 10 trimmed.
The largest buyer was Redmile Group, adding an estimated $4.61M. The largest seller was Jennison Associates, exiting entirely with an estimated $3.08M sold.
- 49 institutional investors held Ovid Therapeutics (OVID) as of Q3 2018, up from 48 in Q2 2018.
- Funds reported $41.9M of Ovid Therapeutics stock for Q3 2018, down 30% quarter-over-quarter.
- 8 funds opened new Ovid Therapeutics positions in Q3 2018 and 7 closed out, a net change of +1 holder.
- The largest Ovid Therapeutics buyer in Q3 2018 was Redmile Group, an estimated $4.61M added.
- The largest Ovid Therapeutics seller in Q3 2018 was Jennison Associates, an estimated $3.08M sold.
Based on aggregated 13F filings for Q3 2018.